Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifebemtinib + PLD in Platinum-Resistant Recurrent Ovarian Cancer
NCT06014528Phase 2Recruiting
- Sponsor
- InxMed
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in ovarian cancer, sponsored by InxMed. Started Sep 2022; status: recruiting.
02
Drugs
ifebemtinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06014528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014528.